Top Clinical Trials companies in Canada by EBITDA Margin
Canada
# |
Name |
EBITDA Margin |
Reported Date | Stock Price |
Change |
Price (30 days) | Country |
|---|---|---|---|---|---|---|---|
| 1 |
53.21%
|
Dec. 31, 2023 | USD 9.51 | -0.80% |
|
Canada |
|
| 2 |
20.43%
|
Dec. 31, 2023 | USD 2.96 | 1.10% |
|
Canada |
|
| 3 |
17.05%
|
March 31, 2024 | USD 2.65 | -1.93% |
|
Canada |
|
| 4 |
12.46%
|
Dec. 31, 2023 | USD 4.00 | 3.39% |
|
Canada |
|
| 5 |
-12.06%
|
Nov. 30, 2023 | USD 1.52 | 2.02% |
|
Canada |
|
| 6 |
-35.92%
|
Dec. 31, 2023 | USD 7.95 | -0.62% |
|
Canada |
|
| 7 |
-158.79%
|
Dec. 31, 2023 | USD 14.60 | -0.95% |
|
Canada |
|
| 8 |
-223.48%
|
Dec. 31, 2023 | USD 1.22 | 2.52% |
|
Canada |
|
| 9 |
-372.01%
|
Dec. 31, 2023 | USD 6.23 | -0.19% |
|
Canada |
|
| 10 |
-505.35%
|
Dec. 31, 2023 | USD 3.17 | -1.86% |
|
Canada |
|
| 11 |
-5,684.50%
|
Dec. 31, 2023 | USD 1.97 | -2.48% |
|
Canada |
Frequently Asked Questions
-
Which Clinical Trials company in Canada has the highest EBITDA Margin ?
The Clinical Trials company in Canada with the highest EBITDA Margin is Cipher Pharmaceuticals Inc. (Toronto Stock Exchange: CPH.TO) at 53.21%.
-
Which Clinical Trials company in Canada has the lowest EBITDA Margin ?
The Clinical Trials company in Canada with the lowest EBITDA Margin is Milestone Pharmaceuticals Inc. (NasdaqGS: MIST) at -5,684.50%.
-
What are the top 10 Clinical Trials companies in Canada by EBITDA Margin ?
The top 10 Clinical Trials companies in Canada by EBITDA Margin are Cipher Pharmaceuticals Inc., HLS Therapeutics Inc., Medexus Pharmaceuticals Inc., Knight Therapeutics Inc., Theratechnologies Inc., Aurinia Pharmaceuticals Inc., Zymeworks Inc., Repare Therapeutics Inc., Profound Medical Corp. and AbCellera Biologics Inc..
-
What are the bottom 10 Clinical Trials companies in Canada by EBITDA Margin ?
The bottom 10 Clinical Trials companies in Canada by EBITDA Margin are Milestone Pharmaceuticals Inc., AbCellera Biologics Inc., Profound Medical Corp., Repare Therapeutics Inc., Zymeworks Inc., Aurinia Pharmaceuticals Inc., Theratechnologies Inc., Knight Therapeutics Inc., Medexus Pharmaceuticals Inc. and HLS Therapeutics Inc..
